Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 11/20 | 0.62 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.62 |
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.52 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.52 |
| ▸ | KDM6B | O15054 | 4/20 | 0.48 |
| ▸ | KDM3A | Q9Y4C1 | 4/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | HIF1AN | Q9NWT6 | 3/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704958 | 0.77 | FTO (1.00) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL352338 | 0.74 | HCAR2 (0.40) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL1219748 | 0.71 | P2RX7 (0.64) | FTOEGLN2EGLN1KDM4C | |
| SCHEMBL19691158 | 0.69 | KMT2A (0.37) | — | |
| SCHEMBL18647986 | 0.68 | EGLN1 (0.59) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL29045546 | 0.68 | EGLN1 (0.63) | FTOEGLN2EGLN1EGLN3VEGFA | |
| SCHEMBL1920739 | 0.67 | EGLN1 (0.67) | FTOEGLN2EGLN1EGLN3VEGFA | |
| SCHEMBL6567473 | 0.66 | EGLN1 (0.54) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL29045423 | 0.66 | EGLN1 (0.57) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL821712 | 0.66 | KDM4C (0.58) | FTOEGLN2EGLN1KDM5BKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104427980-A | Treatment for high cholesterol | FIBROGEN INC | 2015-03-18 | — | — | CN | disclosed |
| US-20140309256-A1 | Therapeutic Method | FIBROGEN, INC | 2014-10-16 | — | — | US | disclosed |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | FIBROGEN, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110275697-A1 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. | 2011-02-17 | — | — | US | disclosed |
| CN-101917996-A | Methods for reducing blood pressure | FIBROGEN INC | 2010-12-15 | — | — | CN | disclosed |
| EP-2250264-A2 | REGULATION OF CYCLIN D | Dana-Farber Cancer Institute, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-2222305-A1 | METHODS FOR REDUCING BLOOD PRESSURE | Fibrogen, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010024911-A1 | METHODS FOR INCREASING NEUROGENESIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009102469-A2 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009058403-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | FTO 4088/4885EGLN2 215/4885EGLN1 238/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | FTO 4102/4885EGLN2 866/4885EGLN1 1148/4885 |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | HMGCR, MB, PDE3A | FTO 3686/4885EGLN2 284/4885EGLN1 1790/4885 |
| US-20110275697-A1 | REGULATION OF CYCLIN D | EGLN2, EGLN1, EGLN3 | FTO 4043/4885EGLN2 1/4885EGLN1 2/4885 |
| US-20140309256-A1 | Therapeutic Method | HIF1AN, EGLN3, EGLN2 | FTO 1807/4885EGLN2 3/4885EGLN1 6/4885 |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | HMGCR, MB, PDE3A | FTO 3686/4885EGLN2 284/4885EGLN1 1790/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | FTO 3763/4885EGLN2 505/4885EGLN1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.